Clinical trials: WNT Pathway
Knee Osteoarthritis
Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis…
- Trial name
- STRIDES-1 (NCT04385303)
- Testing
- Lorecivivint
- Where
- 76 sites in United States
- Volunteers
- 496 people
- Sponsor
- Biosplice Therapeutics, Inc.
Knee Osteoarthritis
Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic…
- Trial name
- STRIDES-Xray (NCT03928184)
- Testing
- Lorecivivint
- Where
- 99 sites in United States
- Volunteers
- 501 people
- Sponsor
- Biosplice Therapeutics, Inc.
Hepatocellular Carcinoma (HCC)
Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma
The goal of this clinical trial is to evaluate the combination of zanzalintinib (XL092) and tegavivint in advanced hepatocellular carcinoma (HCC) and Wnt pathway mutations who have progressed after at least one prior line of…
- Trial name
- NCT07878689
- Testing
- Zanzalintinib, Tegavivint
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Colorectal Cancer
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
The purpose of this study is to assess the safety and anti-tumor activity of the triple combination of WNT974, LGX818 and cetuximab in BRAFV600-mutant mCRC with RNF43 mutations or RSPO fusions.
- Trial name
- NCT02278133
- Testing
- WNT974, LGX818, Cetuximab
- Where
- 19 sites in United States, Australia and 8 more
- Volunteers
- 20 people
- Sponsor
- Array BioPharma
Solid Tumors
DPTX3186 in Wnt Pathway Activated Solid Tumors
This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist.
- Trial name
- NCT07312903
- Testing
- DPTX3186
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dewpoint Therapeutics
Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.
- Conditions
- Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, GastroEsophageal Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04681248
- Testing
- DKN-01
- Where
- 5 sites in United States
- Sponsor
- Leap Therapeutics, Inc.
Degenerative Disc Disease
A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease
SM04690-DDD-01 is a Phase 1, open-label, dose escalation study. SM04690 Injectable Suspension will be administered via a single intradiscal injection to subjects with degenerative disc disease (DDD) under fluoroscopic guidance.
- Trial name
- NCT03246399
- Testing
- SM04690
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Biosplice Therapeutics, Inc.
Colon Cancer
A Study of Niclosamide in Patients With Resectable Colon Cancer
This study evaluates the safety of Niclosamide in patients with colon cancer that are undergoing primary resection of their tumor. This is a phase I study with three dosage levels to determine the maximum tolerated dose (MTD).
- Trial name
- NCT02687009
- Testing
- Niclosamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Michael Morse, MD
Esophageal Cancer
Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During Staging of Esophageal Cancer Patients
Cancer results when undifferentiated cells grow in an uncontrolled manner, crowding out normal cells, causing morbidity and ultimately mortality.
- Trial name
- NCT02221245
- Testing
- Tumor Biopsy via Ultrasound Endoscopy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Miami